• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Association between Red Blood Cell Distribution Width and Mortality and Severity among Patients with COVID-19: A Systematic Review and

tetano

Editor, Senior Moderator
J Med Virol


. 2021 Jan 15.
doi: 10.1002/jmv.26797. Online ahead of print.
Association between Red Blood Cell Distribution Width and Mortality and Severity among Patients with COVID-19: A Systematic Review and Meta-Analysis


Jane J Lee[SUP] 1 [/SUP], Sahar Memar Montazerin[SUP] 2 [/SUP], Adeel Jamil[SUP] 3 [/SUP], Umer Jamil[SUP] 3 [/SUP], Jolanta Marszalek[SUP] 4 [/SUP], Michael L Chuang[SUP] 2 [/SUP], Gerald Chi[SUP] 2 [/SUP]



Affiliations

Abstract

Emerging evidence has underscored the potential usefulness of red blood cell distribution width (RDW) measurement in predicting the mortality and disease severity of COVID-19. This study aimed to assess the association of the plasma RDW levels with adverse prognosis in COVID-19 patients. A comprehensive literature search from inception to September 2020 was performed to harvest original studies reporting RDW on admission and clinical outcomes among patients hospitalized with COVID-19. RDW levels were compared between cases (patients who died or developed more severe symptoms) and controls (patients who survived or developed less severe symptoms). A total of 14,866 subjects from 10 studies were included in the meta-analysis. Higher levels of RDW were associated with adverse outcomes in COVID-19 patients (mean differences=0.72; 95% CI=.47-0.97; I[SUP]2[/SUP] =89.51%). Deceased patients had higher levels of RDW compared to survived patients (mean differences=0.93; 95% CI=0.63-1.23; I[SUP]2[/SUP] =85.58%). Severely ill COVID-19 patients showed higher levels of RDW, as opposed to patients classified to have milder symptoms (mean differences=0.61; 95% CI=0.28-0.94; I[SUP]2[/SUP] =82.18%). Elevated RDW levels were associated with adverse outcomes in COVID-19 patients. This finding warrants further research on whether RDW could be utilized as a simple and reliable biomarker for predicting COVID-19 severity and whether RDW is mechanistically linked with COVID-19 pathophysiology. This article is protected by copyright. All rights reserved.

Keywords: COVID-19; biomarkers; erythrocyte indices; red blood cell distribution width; severe acute respiratory syndrome coronavirus 2.
 
Back
Top Bottom